Hai-Zheng Pharmaceutical: HS387 tablets receive approval for new drug clinical trials from the US FDA.

Hai Zheng Pharmaceutical announced that the company's application for clinical trials of the HS387 tablet drug has been approved by the US FDA and can be conducted in the United States. The drug is a selective KIF18A inhibitor independently developed by the company, intended for the treatment of advanced solid tumors, and has previously received clinical trial approval from the National Medical Products Administration. Currently, there are multiple KIF18A inhibitors in clinical development both domestically and internationally, but none have been marketed yet. However, the approval and market launch of the drug still require a series of clinical trials to be conducted, which will not have a significant short-term impact on the company's business operations. Investors are reminded to pay attention to the risks.